These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22377753)

  • 1. The cost-effectiveness of biopharmaceuticals: a look at the evidence.
    Wilson AW; Neumann PJ
    MAbs; 2012; 4(2):281-8. PubMed ID: 22377753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence.
    Zhong Y; Lin PJ; Cohen JT; Winn AN; Neumann PJ
    Value Health; 2015 Mar; 18(2):308-14. PubMed ID: 25773567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.
    Neumann PJ; Fang CH; Cohen JT
    Pharmacoeconomics; 2009; 27(10):861-72. PubMed ID: 19803540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The changing face of the cost-utility literature, 1990-2012.
    Neumann PJ; Thorat T; Shi J; Saret CJ; Cohen JT
    Value Health; 2015 Mar; 18(2):271-7. PubMed ID: 25773562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The State of Cost-Utility Analyses in Asia: A Systematic Review.
    Thorat T; Lin PJ; Neumann PJ
    Value Health Reg Issues; 2015 May; 6():7-13. PubMed ID: 29698196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analyses of diagnostic laboratory tests: a systematic review.
    Fang C; Otero HJ; Greenberg D; Neumann PJ
    Value Health; 2011 Dec; 14(8):1010-8. PubMed ID: 22152169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.
    Zhou T; Chen Z; Li H; Xie F
    Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures.
    Chambers J; Pope E; Bungay K; Cohen J; Ciarametaro M; Dubois R; Neumann PJ
    Value Health; 2018 Apr; 21(4):400-406. PubMed ID: 29680096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adoption of cost-effectiveness acceptability curves in cost-utility analyses.
    Meckley LM; Greenberg D; Cohen JT; Neumann PJ
    Med Decis Making; 2010; 30(3):314-9. PubMed ID: 19773582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and quality of the cost-utility literature, 1976-2001.
    Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
    Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis in spine care: a systematic review.
    Kepler CK; Wilkinson SM; Radcliff KE; Vaccaro AR; Anderson DG; Hilibrand AS; Albert TJ; Rihn JA
    Spine J; 2012 Aug; 12(8):676-90. PubMed ID: 22784806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the value for money of medicines? A registry study.
    Simoens S
    J Clin Pharm Ther; 2012 Apr; 37(2):182-6. PubMed ID: 21812796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in the measurement of health utilities in published cost-utility analyses.
    Brauer CA; Rosen AB; Greenberg D; Neumann PJ
    Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family Spillover Effects in Pediatric Cost-Utility Analyses.
    Lavelle TA; D'Cruz BN; Mohit B; Ungar WJ; Prosser LA; Tsiplova K; Vera-Llonch M; Lin PJ
    Appl Health Econ Health Policy; 2019 Apr; 17(2):163-174. PubMed ID: 30350218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
    Picavet E; Cassiman D; Simoens S
    J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.
    Greenberg D; Earle C; Fang CH; Eldar-Lissai A; Neumann PJ
    J Natl Cancer Inst; 2010 Jan; 102(2):82-8. PubMed ID: 20056956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can cost utility evaluations inform decision making about interventions for low back pain?
    Dagenais S; Roffey DM; Wai EK; Haldeman S; Caro J
    Spine J; 2009 Nov; 9(11):944-57. PubMed ID: 19748833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics of market access for biopharmaceuticals and biosimilars.
    Simoens S
    J Med Econ; 2009 Sep; 12(3):211-8. PubMed ID: 19723019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.